http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101208198-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-322 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L29-035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L29-045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate | 2010-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101208198-B1 |
| titleOfInvention | A pharmaceutical composition for the treatment or prevention of Parkinson's disease, which contains a compound having LLRR2 kinase inhibitory activity as an active ingredient. |
| abstract | The present invention relates to a composition for treating or preventing Parkinson's disease, which contains a compound having LRRK2 kinase inhibitory activity as an active ingredient, wherein the compound is an LRRK2 kinase inhibitor and is oxidative stress-induced cytotoxicity due to overexpression of LRRK2 mutant protein. Because it can suppress the can be useful as a drug or food for treating or preventing Parkinson's disease. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210118735-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021194144-A1 |
| priorityDate | 2010-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.